-
ASSESSING THE RETURN ON INVESTMENT (ROI) OF HEOR & RWE TO THE BIOPHARMACEUTICAL INDUSTRY: CASE EXAMPLE OF ECONOMIC MODELING IN HEALTH TECHNOLOGY ASSESSMENT (HTA) SUBMISSIONS
Mar 18, 2026, 21:38 PM -
CLAIMS DATABASE ANALYSIS TO ASSESS THE COMPLEXITY AND SEVERITY OF PATIENT CASES, DISEASE BURDEN, AND HEALTH CARE RESOURCE UTILIZATION (HCRU) IN US BARTH SYNDROME PATIENTS
Mar 18, 2026, 21:38 PM -
THE SCALE OF PROLONGED UNCERTAINTY: ESTIMATING U.S. PATIENT POPULATIONS AFFECTED BY OVERDUE ACCELERATED APPROVAL CONFIRMATORY TRIALS
Mar 18, 2026, 21:38 PM -
VALIDATION OF THE METASLR ROB MODULE: A MULTI-AGENT GENERATIVE AI SYSTEM FOR AUTOMATING COCHRANE RISK OF BIAS 2.0 ASSESSMENTS
Mar 18, 2026, 21:38 PM -
BUDGET IMPACT OF INTRODUCING TAPINAROF, A NEW ARYL HYDROCARBON RECEPTOR AGONIST, FOR THE TREATMENT OF ATOPIC DERMATITIS IN ADULT AND PEDIATRIC PATIENTS, FROM A U.S. MEDICAID PLAN PERSPECTIVE
Mar 18, 2026, 21:38 PM -
MACHINE LEARNING-BASED PREDICTION FOR NEPHROTOXICITY IN ONCOLOGY PATIENTS WITH CHEMOTHERAPY
Mar 18, 2026, 21:38 PM -
REPRESENTATIVENESS OF LINKED CLAIMS-EHR DATA: CLAIMS-ONLY VS CLAIMS+EHR POPULATIONS
Mar 18, 2026, 21:38 PM -
CROSS-VALIDATION OF AN EARLY COST-EFFECTIVENESS MODEL FOR SPECTRIS™ THERAPY USING THE ALZHEIMER’S DISEASE OPEN-SOURCE IPECAD MODEL FRAMEWORK
Mar 18, 2026, 21:38 PM -
FROM SINGLE-ARM EVIDENCE TO HTA-READY SURVIVAL COMPARISONS: EXTENDING MULTILEVEL NETWORK META-REGRESSION TO DISCONNECTED NETWORKS FOR TIME-TO-EVENT OUTCOMES IN NEWLY DIAGNOSED MULTIPLE MYELOMA
Mar 18, 2026, 21:38 PM -
CHARACTER STRENGTHS AND BURNOUT DIMENSIONS AMONG EMERGENCY CARE PROFESSIONALS IN HUNGARY: A CROSS-SECTIONAL STUDY
Mar 18, 2026, 21:38 PM -
FIRST-LINE SYSTEMIC TREATMENT PATTERNS IN METASTATIC UROTHELIAL CARCINOMA IN US COMMUNITY ONCOLOGY PRACTICES
Mar 18, 2026, 21:38 PM -
EMPLOYEE PERCEPTIONS AND EXPERIENCES WITH TIRZEPATIDE TREATMENT FOR OBESITY OR OVERWEIGHT IN THE US
Mar 18, 2026, 21:38 PM -
MODELING THE IMPACT OF SOTATERCEPT ON MORBIDITY AND MORTALITY IN PULMONARY ARTERIAL HYPERTENSION: A MEXICAN POPULATION HEALTH PERSPECTIVE
Mar 18, 2026, 21:38 PM -
HEALTH ECONOMICS PUBLISHED EVIDENCE FOR FDA-APPROVED DRUGS (2022-2023): AVAILABILITY, TIMING & DISSEMINATION PATHWAY
Mar 18, 2026, 21:38 PM -
COMPARING AN EXPERT-IN-THE-LOOP AI WORKFLOW WITH MANUAL SYSTEMATIC LITERATURE REVIEW: IMPLICATIONS FOR EFFICIENCY AND EVIDENCE QUALITY IN HEOR
Mar 18, 2026, 21:38 PM -
ELEVATE GEN-AI FRAMEWORK-BASED INTERIM EVALUATION OF A GENAI-ENABLED PLATFORM FOR LITERATURE SCREENING OF A CLASS II MEDICAL DEVICE
Mar 18, 2026, 21:38 PM -
HOW INDIVIDUALS CHOOSE MEDICATIONS: A DISCRETE CHOICE EXPERIMENT TO UNDERSTAND MANAGEMENT OF EYE ALLERGY RX TO OTC TREATMENT DECISIONS
Mar 18, 2026, 21:38 PM -
HEALTHCARE COST ASSOCIATED WITH CARDIOVASCULAR-KIDNEY-METABOLIC (CKM) SYNDROME STAGES AMONG ADULTS IN THE UNITED STATES: ANALYSIS OF NATIONALLY REPRESENTATIVE DATA
Mar 18, 2026, 21:38 PM -
GENERAL-PURPOSE VERSUS DOMAIN-SPECIFIC AI FOR SYSTEMATIC CONFOUNDER IDENTIFICATION IN MULTIPLE SCLEROSIS: A COMPARATIVE METHODOLOGICAL STUDY USING IQWIG ASSESSMENTS AS GROUND TRUTH
Mar 18, 2026, 21:38 PM -
REGULATORY CHALLENGES AND INSIGHTS FROM FDA IN 2025; POTENTIAL IMPLICATIONS OF THE PLAUSIBLE MECHANISM PATHWAY AND SUBSEQUENT HEALTH TECHNOLOGY ASSESSMENTS
Mar 18, 2026, 21:38 PM
